Effects of Troglitazone on Insulin Sensitivity

@article{Henry1996EffectsOT,
  title={Effects of Troglitazone on Insulin Sensitivity},
  author={Robert R. Henry},
  journal={Diabetic Medicine},
  year={1996},
  volume={13}
}
  • R. Henry
  • Published 1 September 1996
  • Medicine
  • Diabetic Medicine
Studies to date confirm that troglitazone has therapeutic benefits to NIDDM and can normalize JGT in those individuals at increased risk of developing NIDDM. Hyperinsulinaemia is reduced by such treatment in association with reduced insulin resistance and there are favourable effects on blood pressure with troglitazone therapy as well. Since insulin resistance and hyperinsulinaemia are usually present in obesity and impaired glucose tolerance (IGT), troglitazone may be useful in preventing the… 

Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.

Troglitazone has been shown to exert additional beneficial effects on serum lipid profile and arterial blood pressure, and may be considered as a valuable alternative in insulin-resistant (obese and hyperinsulinemic) diabetic patients who appear to be the best responders to the drug.

Thiazolidinediones Could Improve Endothelial Dysfunction and Risk of Premature Coronary Heart Disease in HIV-Infected Patients

An increasing totality of evidence suggests that TZDs may represent a unique and powerful research tool to find a common denominator underlying the pathophysiology and treatment of the metabolic cardiovascular risk factors associated with HIV infection.

Thiazolidinedione compounds: a patent review (2010 – present)

The present review provides an extended study of chemistry and inhibitory activity of established drug candidates containing TZDs, viz. their patenting scenario and covers TZD-based antidiabetic, anticancer and antimalarial drugs.

Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes

The HOMA-CIGMA test with immunoreactive insulin provides similar information in distinguishing insulin sensitivity between subjects with normal glucose tolerance, those with impaired glucose tolerance and those with Type II diabetes as does FSIVGTT, whereas ITT is less informative.

Pathogenesis and treatment of lipodystrophy: what clinicians need to know.

  • F. Sattler
  • Medicine, Biology
    Topics in HIV medicine : a publication of the International AIDS Society, USA
  • 2008
This article summarizes a presentation on lipodystrophy made by Fred R. Sattler, MD, at an International AIDS Society--USA Continuing Medical Education course in Washington, DC, in May 2008, and recommends starting treatment with regimens that include drugs associated with lower risk of lipoatrophy.

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.

Results suggest troglitazone is a potent inhibitor of VSMC proliferation and migration and, thus, may be a useful agent to prevent restenosis and possibly atherosclerosis.

The Mechanism of Hematoxylin on Glucose Metabolism Improvement in Sciatic Nerves from Streptozotocin-induced Diabetic Rats.

It is proposed that hematoxylin can be a promising candidate for diabetes medication because it increases glucose transport and lipid metabolism by partially normalizing concerned with myo-inositol metabolism in diabetic rat.

Das HIV-Proteasehemmer-induzierte Insulinresistenzsyndrom

Therapy with HIV protease inhibitors should include regular monitoring of metabolic alterations and cardiovascular damage and Particularly patients with genetic or traditional risk factors for type 2 diabetes should be monitored frequently.

Nebenwirkungen der antiretroviralen Therapie

With increasing duration of therapy metabolic alterations such as hyperlipidemia, diabetes mellitus type 2 and lipodystrophy are encountered which considerably reduced quality of life for the patients, most likely due to protease inhibitors and nucleoside analogues with synergistic effects.

References

SHOWING 1-10 OF 10 REFERENCES

Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM

CS-045 is effective in improving glucose tolerance without stimulation of insulin secretion in NIDDM, suggesting an effect in improving insulin sensitivity.

Role of Insulin Resistance in Human Disease

The possibility is raised that resistance to insulin-stimulated glucose uptake and hyperinsulinemia are involved in the etiology and clinical course of three major related diseases— NIDDM, hypertension, and CAD.

Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects

CS-045 improves insulin resistance, reduces insulinemia, lowers hepatic glucose production, and improves both fasting and postprandial glycemia in NIDDM subjects.

Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats

It is suggested that CS-045 increases not only insulin sensitivity but also insulin responsiveness, and may reduce abnormalities of glucose and lipid metabolism in obese and non-insulin-dependent diabetes mellitus patients with insulin resistance.

Improvement in glucose tolerance in obese subjects treated with troglitazone. N Eng

  • J Med
  • 1994

Improvement in glucose tolerance in obese subjects treated with troglitazone

  • N Eng/ J Med
  • 1994

Introduction: pathogenesis of insulin resistance and hyperglycaemia in NIDDM

  • Am J Med 1985;79 (suppl
  • 1985